Cita APA

Santiago-Setien, P., Barquín-Rego, C., Hernández-Martínez, P., Ezquerra-Marigomez, M., Torres-Barquín, M., Menéndez-Garcia, C., . . . Riancho Zarrabeitia, J. (2023). Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.

Citación estilo Chicago

Santiago-Setien, Pilar, et al. Switch to Ocrelizumab in MS Patients Treated With Natalizumab in Extended Interval Dosing At High Risk of PML: A 96-week Follow-up Pilot Study. 2023.

Cita MLA

Santiago-Setien, Pilar, et al. Switch to Ocrelizumab in MS Patients Treated With Natalizumab in Extended Interval Dosing At High Risk of PML: A 96-week Follow-up Pilot Study. 2023.